載入中
NASDAQHealthcareMedical - Healthcare Information Services
最新資料
US$14.78
+US$0.36 · +2.50%
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
收盤時
US$14.78
+US$0.36 · +2.50%
盤後
US$14.71
−US$0.07 · -0.47%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
日內區間
目前US$14.78
52週區間
目前US$14.78
盤中時間採用ET。市場資料可能有所延遲。
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
日內區間
目前US$14.78
52週區間
目前US$14.78
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.50
上漲空間 25.17%價格歷史記錄不可用
最高：US$20.00平均的：US$18.50最低：US$17.00AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
